Shares of Organovo Holdings, Inc. (NASDAQ:ONVO), a 3D biology company, rose by as much as 10.5% in early morning trading today. The company's shares got a lift from a data presentation at the TERMIS-Americas Meeting showing the survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models.
The global liver transplant market is desperately short of donor organs. As such, a 3D bioprinted human liver could potentially generate hundreds of millions -- or perhaps billions -- in revenue for its manufacturer.
Before investors get too excited, though, it's important to bear in mind that Organovo is only presenting preclinical data of its 3D bioprinted human liver technology at this meeting. So, while this technology could eventually be used to meet a tremendous unmet medical need in the liver transplant space, it is several years away from potentially reaching the market as a direct surgical implant in human patients.
In the meantime, investors should keep a close eye on the company's ability to build out the market for its ExVive human kidney and liver tissue services. The fact of the matter is that this novel technology still has a long ways to go in terms of realizing its commercial potential.
After all, the Street is forecasting Organovo's revenue to come in at a meager $5.5 million next year, which is a drop in the bucket compared to the company's internal estimates of billion-dollar addressable markets down the road.